11 November 2014 | News | By BioSpectrum Bureau
IFPMA announces its new President
He had been vice president at IFPMA since 2012
Mr Stefan Oschmann, CEO pharma and member of the executive board of Merck, was elected the President of IFPMA (International Federation of Pharmaceutical Manufacturers and Associations) during 27th IFPMA Assembly. Previously, he was the vice president at IFPMA since 2012. He succeeds Mr John Lechleiter, chairman, president and CEO of the executive board of Eli Lilly.
"I plan to focus my presidency on 'accelerating access' to quality health solutions for people in low and middle income countries to contribute to the sustainability challenge. Much progress has been achieved in expanding access to health in these countries but the call for 'accelerating access' demonstrates that there is still so much that needs to be done and only together can we make a lasting difference," said Mr Oschmann.